New Hepatitis C treatments cost-effective, but only for selected patients

While new therapies to treat Hepatitis C Virus are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients, a new study concludes. The study focused on the combination of sofosbuvir and ribavirin for treatment of HCV genotypes 2 and 3, which account for approximately one quarter of all HCV cases in the United States.



from Today's Healthcare News -- ScienceDaily http://ift.tt/19KCMGB